Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structureKawanishi, N., Sugimoto, T., Shibata, J., Nakamura, K., Masutani, K., Ikuta, M., Hirai, H.
(2006) Bioorg Med Chem Lett 16: 5122-5126
- PubMed: 16876403
- DOI: https://doi.org/10.1016/j.bmcl.2006.07.026
- Primary Citation of Related Structures:
- PubMed Abstract:
The design of a novel series of cyclin-dependent kinase (CDK) inhibitors containing a macrocyclic quinoxaline-2-one is reported. Structure-based drug design and optimization from the starting point of diarylurea 2, which we previously reported as a moderate CDK1,2,4,6 inhibitor [J. Biol.Chem.2001, 276, 27548], led to the discovery of potent CDK1,2,4,6 inhibitor that were suitable for iv administration for in vivo study.
Department of Medicinal Chemistry, Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories, Okubo-3, Tsukuba 300-2611, Ibaraki, Japan. email@example.com